ArticleCureus2025
Epidemiology of Cerebral Venous Sinus Thrombosis: 2021-2023.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Venous-significant intracranial hemorrhage in neonatal HIE treated with therapeutic hypothermia: imaging phenotypes, diagnostic pitfalls, and prognostic implications.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral venous sinus thrombosis (CVST) is a high-risk, low-prevalence disease. Presentations can be variable, and diagnosis often requires magnetic resonance venography, making diagnosis challenging. To date, no studies have focused on patients presenting to the emergency department (ED) who were ultimately diagnosed with CVST. We conducted a cross-sectional study using Cosmos (Epic Systems Corporation), a large de-identified electronic health record database. Our objective was to describe the ED encounter rate, demographic characteristics, clinical features, medications, and outcomes of adult patients with CVST between 2021 and 2023. Our age distribution indicates that CVST occurs more frequently in older adults than previously thought. Headache was the most common chief complaint. Co-presentation with head injury and malignancy was also frequent. Most patients underwent some form of neuroimaging and received anticoagulation. In this large, nationally representative ED cohort, CVST was rare; however, prospective studies are needed to better understand the risk factors, diagnostic approaches, and medical management of CVST in patients presenting to the ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.